PLIVA entered into a deal with Legacy Pharma, for the sale of the CNS franchise of PLIVA’s US subsidiary, Odyssey Pharmaceuticals for US$62.5 M. The franchise consists of three marketed products - Antabuse®, Vivactil® and Surmontil®.